Compositions and their uses directed to il-4r alpha

Abstract

Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-α, airway hyperresponsiveness, and / or pulmonary inflammation.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application Ser. Nos. 60 / 656,760, filed Feb. 25, 2005; 60 / 688,897, filed Jun. 9, 2005; 60 / 700,656, filed Jul. 19, 2005; and 60 / 709,404 filed Aug. 18, 2005; all of which are incorporated herein by reference in their entirety.INCORPORATION OF SEQUENCE LISTING[0002]A copy of the sequence listing in both a paper and a computer-readable form is provided herewith and hereby incorporated by reference. The computer readable form is provided on 3.5″ diskette containing the file named RTS0792WOSEQ.txtBACKGROUND OF THE INVENTION[0003]Allergic rhinitis and asthma are widespread conditions with complex and multifactorial etiologies. The severity of the conditions vary widely between individuals, and within individuals, dependent on factors such as genetics, environmental conditions, and cumulative respiratory pathology associated with duration and severity of disease. Both diseases are a resu...

AI Technical Summary

Benefits of technology

The invention provides compounds that target a specific gene called IL-4R alpha, which is associated with pulmonary inflammation and airway hyperresponsiveness. These compounds are designed to decrease the expression of IL-4R alpha and can be administered through various delivery methods such as nebulizers and nasal inhalers. The invention also provides a method for using these compounds to treat or prevent diseases associated with pulmonary inflammation and airway hyperresponsiveness. The technical effect of the invention is to provide a targeted approach for treating inflammatory diseases of the lung.

Problems solved by technology

In asthma, the pathology manifests as inflammation, mucus overproduction, and reversible airway obstruction which may result in scarring and remodeling of the airways.

However, moderate and severe asthma are less well controlled, and require daily treatment with more than one long-term control medication to achieve consistent control of asthma symptoms and normal lung function.

Although LABA can decrease dependence on corticosteroids, they are not as effective for total asthma control as corticosteroids (e.g., reduction of episodes, emergency room visits) (Lazarus et al., JAMA.

Severe asthmatics often suffer from chronic symptoms, including night time symptoms; limitations on activities; and the need for emergency room visits.

Additionally, chronic corticosteroid therapy at any level has a number of unwanted side effects, especially in children (e.g., damage to bones resulting in decreased growth).

Antihistamines are utilized to block itching and sneezing and many of these drugs are associated with side effects such as sedation and performance impairment at high doses.

Decongestants frequently cause insomnia, tremor, tachycardia, and hypertension.

Nasal formulations, when taken improperly or terminated rapidly, can cause rebound congestion.

Anticholinergics and montelukast have substantially fewer side effects, but they also have limited efficacy.

Similarly, prescription medications are not free of side effects.

Nasal corticosteroids can be used for prophylaxis or suppression of symptoms; however, compliance is variable due to side effects including poor taste and nasal irritation and bleeding.

Allergen immunotherapy is expensive and time consuming and carries a low risk of anaphylaxis.

Persistent nasal inflammation can result in the development of nasal polyps.

Chronic inflammation causes a reactive hyperplasia of the intranasal mucosal membrane, which results in the formation of polyps.

Intranasal steroid sprays may reduce or retard the growth of small nasal polyps, but they are relatively ineffective in massive nasal polyposis.

Although nasal polyps can be treated pharmacologically, many of the therapeutics have undesirable side effects.

Moreover, polyps tend to be recurrent, eventually requiring surgical intervention.

Compositions and methods to inhibit post-surgical recurrence of nasal polyps are not presently available.

However, treatment with any ASO targeted to any inflammatory mediator involved in pulmonary inflammation is not always effective at reducing AHR and / or pulmonary inflammation.

Treatment with each of two different antisense oligonucleotides targeted to JNK-1 were not effective at reducing methacholine induced AHR, eosinophil recruitment, or mucus production at any of the ASO doses tested.

Although it is suggested in these publications that the ASOs and siRNAs can be used in pharmaceutical compositions, there are no data demonstrating the efficacy of the compounds in vivo for the prevention, amelioration, and / or treatment of any disease or disorder.